drugset / Trial / NCT04134884
Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast Cancer
Phase 1
Completed
34 enrolled
Kathy Miller
Astex Pharmaceuticals, Inc. · collabPfizer · collabVan Andel Institute Stand Up to Cancer Team · collab
NaSequentialOpen-labelTreatment
Summary
This is a Phase I study to test the safety of a combination of ASTX727 with talazoparib in patients with triple negative breast cancer or hormone resistant/HER2-negative metastatic breast cancer
Timeline
- Start
- 2020-04-01
- Primary completion
- 2024-01-30
- Completion
- 2024-03-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ASTX727 | Unknown | 10 mg | — |
| Subject | ASTX727 | Unknown | 15 mg | — |
| Subject | Talazoparib | Small molecule | 0.25 mg | — |
| Subject | Talazoparib | Small molecule | 0.5 mg | — |
| Subject | Talazoparib | Small molecule | 0.75 mg | — |
| Subject | Talazoparib | Small molecule | 1 mg | — |